Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791072 | 0.88 | CYP1A2 (0.59) | CYP1A2MME | |
| SCHEMBL5963814 | 0.87 | GRIK1 (0.44) | GRIK1GRIK2CYP1A2MMEPPARG | |
| SCHEMBL6789903 | 0.83 | PPARA (0.51) | GRIK1GRIK2PPARGPPARA | |
| SCHEMBL2397308 | 0.81 | CYP1A2 (0.48) | CYP1A2MMEPPARGPPARAMEN1 | |
| SCHEMBL7378715 | 0.80 | CYP1A2 (0.65) | CYP1A2PPARGPPARAMEN1KMT2A | |
| SCHEMBL27719461 | 0.80 | CYP1A2 (0.47) | CYP1A2MMEPPARGPPARAMEN1 | |
| SCHEMBL7436695 | 0.78 | CYP1A2 (0.57) | CYP1A2PPARGPPARA | |
| SCHEMBL7436701 | 0.78 | CYP1A2 (0.57) | CYP1A2PPARGPPARA | |
| SCHEMBL14571474 | 0.78 | MME (0.47) | CYP1A2MMEPPARGPPARA | |
| SCHEMBL11529738 | 0.75 | CYP1A2 (0.59) | CYP1A2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PETER DRAGOVICH S (US) | 2004-04-15 | — | — | US | disclosed |
| US-6649639-B2 | Inhibit or block the biological activity of the picornaviral 3C protease. | DRAGOVICH PETER S (US) | 2003-11-18 | — | — | US | disclosed |
| EP-0975588-B1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | DRAGOVICH PETER S (US) | 2002-03-14 | — | — | US | disclosed |
| US-6331554-B1 | PICORNAVIRUS PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0975588-A1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6020371-A | VIRICIDES; PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1998043950-A1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | RNASEL, RNASE1, GTF3C3 | GRIK1 3932/4885GRIK2 4225/4885CYP1A2 2658/4885 |
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PCNA, ZC3HAV1, POLR1C | GRIK1 3525/4885GRIK2 4032/4885CYP1A2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.